Clinical Trial

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Trial Details
NCT Number NCT06543069
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Malignant Peritoneal Mesothelioma, Advanced
Enrollment 28 participants
Start Date 2024-01-31
Primary Completion 2026-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-07